Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)

Hypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chewing, and vaping), together with a pro-inflammatory and procoagulant state, are the main risk factors related to atherosclerotic cardiovascular disease. Objective and methods: A group of experts from the America...

Full description

Autores:: Ponte-Negretti, Carlos I.
S. Wyss, Fernando
Piskorz, Daniel
D Santos, Raul
Villar, Raul
Lorenzatti, Alberto
López-Jaramillo, Patricio
Toth, Peter
J. Amaro, A. Juan
Rodrigo, Alfonso K.
Lanas, Fernando
Urina-Triana, Miguel
Lara, Jofre
Valdés, T. Osiris
Gomez-Mancebo, José R.
Bryce, Alfonso
Cobos S, Leonardo
Puente-Barragan, Adriana
Ullauri-Solórzano, Vladimir E.
Medina-Palomino, Felix A.
Lozada, Alfredo F.
Duran, Maritza
Berrospi, Percy
Miranda, David
Badimon, Juan J.
R. González, J. José
Libby, Peter

Tipo de recurso:

Fecha de publicación:: 2021

Institución:: Universidad Simón Bolívar

Repositorio:: Repositorio Digital USB

Idioma:: eng

id	USIMONBOL2_1ce591cae9a554d98280ec59ce1993ba
oai_identifier_str	oai:bonga.unisimon.edu.co:20.500.12442/7944
network_acronym_str	USIMONBOL2
network_name_str	Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
dc.title.translated.spa.fl_str_mv	Consenso latinoamericano para el manejo del riesgo residual cardiometabólico. Consenso realizado por la Academia Latinoamericana de Lipidología y Riesgo Cardiometabólico (ALALIP), con el aval de la Sociedad Interamericana de Cardiología (SIAC), la Sociedad Interamericana de Aterosclerosis (IAS) y el Colegio Panamericano de Endotelio (PACE)
title	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
spellingShingle	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE) Residual risk Cardiovascular risk Cardiometabolic risk factors Atherosclerotic cardiovascular disease Inflam- mation Thrombosis Riesgo residual Riesgo cardiovascular Riesgo cardiometabólico Enfermedad cardiovascular ateroscle- rótica Inflamación Trombosis
title_short	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
title_full	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
title_fullStr	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
title_full_unstemmed	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
title_sort	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)
dc.creator.fl_str_mv	Ponte-Negretti, Carlos I. S. Wyss, Fernando Piskorz, Daniel D Santos, Raul Villar, Raul Lorenzatti, Alberto López-Jaramillo, Patricio Toth, Peter J. Amaro, A. Juan Rodrigo, Alfonso K. Lanas, Fernando Urina-Triana, Miguel Lara, Jofre Valdés, T. Osiris Gomez-Mancebo, José R. Bryce, Alfonso Cobos S, Leonardo Puente-Barragan, Adriana Ullauri-Solórzano, Vladimir E. Medina-Palomino, Felix A. Lozada, Alfredo F. Duran, Maritza Berrospi, Percy Miranda, David Badimon, Juan J. R. González, J. José Libby, Peter
dc.contributor.author.none.fl_str_mv	Ponte-Negretti, Carlos I. S. Wyss, Fernando Piskorz, Daniel D Santos, Raul Villar, Raul Lorenzatti, Alberto López-Jaramillo, Patricio Toth, Peter J. Amaro, A. Juan Rodrigo, Alfonso K. Lanas, Fernando Urina-Triana, Miguel Lara, Jofre Valdés, T. Osiris Gomez-Mancebo, José R. Bryce, Alfonso Cobos S, Leonardo Puente-Barragan, Adriana Ullauri-Solórzano, Vladimir E. Medina-Palomino, Felix A. Lozada, Alfredo F. Duran, Maritza Berrospi, Percy Miranda, David Badimon, Juan J. R. González, J. José Libby, Peter
dc.subject.eng.fl_str_mv	Residual risk Cardiovascular risk Cardiometabolic risk factors Atherosclerotic cardiovascular disease Inflam- mation Thrombosis
topic	Residual risk Cardiovascular risk Cardiometabolic risk factors Atherosclerotic cardiovascular disease Inflam- mation Thrombosis Riesgo residual Riesgo cardiovascular Riesgo cardiometabólico Enfermedad cardiovascular ateroscle- rótica Inflamación Trombosis
dc.subject.spa.fl_str_mv	Riesgo residual Riesgo cardiovascular Riesgo cardiometabólico Enfermedad cardiovascular ateroscle- rótica Inflamación Trombosis
description	Hypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chewing, and vaping), together with a pro-inflammatory and procoagulant state, are the main risk factors related to atherosclerotic cardiovascular disease. Objective and methods: A group of experts from the Americas, based on their clinical expertise in cardiology, cardiovascular prevention, and cardiometabolic (CM) diseases, joined together to develop these practical recommendations for the optimal evaluation and treatment of residual CM risk factors in Latin America, using a modified Delphi methodology (details in electronic TSI) to generate a comprehensive CM risk reduction guideline, and through personalized medicine and patient-centered decision, considering the cost-benefit ratio The process was well defined to avoid conflicts of interest that could bias the discussion and recommendations. Results: Residual risk reduction should consider therapeutic options adapt- ed to specific patient needs, based on five treatment objectives: triglyceride-rich lipoproteins, inflammation, impaired glucose metabolism, high blood pressure, and prothrombotic status. Comprehensive control of all CM risk factors should be a priority to deal with this important public health problem and prevent premature deaths. The recommendations in this paper address the evidence-based treatment of CM risk and are intended for clinical application in Latin American countries.
publishDate	2021
dc.date.accessioned.none.fl_str_mv	2021-07-01T16:10:58Z
dc.date.available.none.fl_str_mv	2021-07-01T16:10:58Z
dc.date.issued.none.fl_str_mv	2021
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.eng.fl_str_mv	info:eu-repo/semantics/article
dc.type.spa.spa.fl_str_mv	Artículo científico
dc.identifier.issn.none.fl_str_mv	14059940
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12442/7944
dc.identifier.doi.none.fl_str_mv	10.24875/ACM.21000005
dc.identifier.url.none.fl_str_mv	https://www.archivoscardiologia.com/files/acm_005_21_management.pdf
identifier_str_mv	14059940 10.24875/ACM.21000005
url	https://hdl.handle.net/20.500.12442/7944 https://www.archivoscardiologia.com/files/acm_005_21_management.pdf
dc.language.iso.eng.fl_str_mv	eng
language	eng
dc.rights.none.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.eng.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	pdf
dc.publisher.eng.fl_str_mv	Permanyer
dc.source.spa.fl_str_mv	Archivos de Cardiología de México
dc.source.none.fl_str_mv	(2021)
institution	Universidad Simón Bolívar
bitstream.url.fl_str_mv	https://bonga.unisimon.edu.co/bitstreams/5494ae4f-70a0-4966-a727-c70d23acd39b/download https://bonga.unisimon.edu.co/bitstreams/fa4e43eb-82a1-495c-8e0d-068291d46b3f/download https://bonga.unisimon.edu.co/bitstreams/3a366dc6-e17b-422e-a679-b3937fab61cb/download https://bonga.unisimon.edu.co/bitstreams/13492803-ccda-44d2-86b4-42af5252e7c0/download https://bonga.unisimon.edu.co/bitstreams/3bf574ff-c691-4733-8497-9f7e4aac5071/download https://bonga.unisimon.edu.co/bitstreams/31d5e601-c3e2-4041-b2a2-bb7463e57463/download https://bonga.unisimon.edu.co/bitstreams/f6d2c737-6d0e-454f-a5ae-63f00e186319/download
bitstream.checksum.fl_str_mv	f5f0ec352ebd75d5f64ebfa2dfa2dd55 4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 4e5ad6cbcf1a9173a96e931766174891 4ca57a5ab58253a140e7f00f4147b711 2c444f42af7e3ccbc203417cd8659f1c c12ef096a4a870f1ca8ed66c444dcbd0
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv	repositorio.digital@unisimon.edu.co
_version_	1814076073837592576
spelling	Ponte-Negretti, Carlos I.153d7170-b19f-4e7a-ab68-46eb6f65e617S. Wyss, Fernando5f44459d-5209-4533-af10-a415231d0892Piskorz, Daniel9a95b671-16e2-4cf2-aad2-77dae794949cD Santos, Raulc025f95a-a91a-4dca-8985-2bb2f2a91c86Villar, Raul0319b2fb-36f6-44ed-930f-7d3464bedd23Lorenzatti, Alberto792f0288-6210-406a-b31c-0e8e0e19afbaLópez-Jaramillo, Patricio772e8dd1-e664-44c6-a578-aac11d275747Toth, Petera66fbe3f-623a-4064-8062-7b40b43ddf36J. Amaro, A. Juan1ee5789f-0d06-400a-9a4e-d260f5ae4775Rodrigo, Alfonso K.61e5be4e-4fd5-458b-b454-c25f193a8f42Lanas, Fernando84a58ae9-bb66-48bf-96f9-a284d3073da5Urina-Triana, Miguel8e1197c0-e46f-4f86-80db-4e0f0298d478Lara, Jofref7112a38-901d-4aed-b990-d72abb25c067Valdés, T. Osiris9112a27a-3fb1-41e7-a43a-b9e7b09c5cd8Gomez-Mancebo, José R.63227fb2-511a-477f-b05b-fd0949038ad4Bryce, Alfonso420e9d53-c0c2-40f7-832d-2766d42b606dCobos S, Leonardo9e4d5f56-bfb4-476b-83f6-8eddd4e2cd3fPuente-Barragan, Adriana803beee0-fd96-4a4e-b2bf-368bdb7e2126Ullauri-Solórzano, Vladimir E.1cba54b5-be7a-4d18-bb8e-333d1327292dMedina-Palomino, Felix A.55b70660-6449-45a2-a4c1-9c107b2ff83bLozada, Alfredo F.cd86ce6d-931c-4aab-bc86-bc5034c62cccDuran, Maritza576a7f87-a183-4cd7-a2a9-c6bd1da076beBerrospi, Percyf5dc21b9-b5de-4e05-8938-e404cf2f79beMiranda, David716a4fc1-a3ac-4d8b-ad33-df7a8e236d8cBadimon, Juan J.0213ee5c-20e9-4e58-a5b9-efbfea61e172R. González, J. José13a570e3-2656-4463-9d87-b06909946fc6Libby, Petera2b956ca-039c-4cf8-914d-568472ad890e2021-07-01T16:10:58Z2021-07-01T16:10:58Z202114059940https://hdl.handle.net/20.500.12442/794410.24875/ACM.21000005https://www.archivoscardiologia.com/files/acm_005_21_management.pdfHypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chewing, and vaping), together with a pro-inflammatory and procoagulant state, are the main risk factors related to atherosclerotic cardiovascular disease. Objective and methods: A group of experts from the Americas, based on their clinical expertise in cardiology, cardiovascular prevention, and cardiometabolic (CM) diseases, joined together to develop these practical recommendations for the optimal evaluation and treatment of residual CM risk factors in Latin America, using a modified Delphi methodology (details in electronic TSI) to generate a comprehensive CM risk reduction guideline, and through personalized medicine and patient-centered decision, considering the cost-benefit ratio The process was well defined to avoid conflicts of interest that could bias the discussion and recommendations. Results: Residual risk reduction should consider therapeutic options adapt- ed to specific patient needs, based on five treatment objectives: triglyceride-rich lipoproteins, inflammation, impaired glucose metabolism, high blood pressure, and prothrombotic status. Comprehensive control of all CM risk factors should be a priority to deal with this important public health problem and prevent premature deaths. The recommendations in this paper address the evidence-based treatment of CM risk and are intended for clinical application in Latin American countries.Un grupo de factores de riesgo cardiometabólicos (hipertensión, hiperglucemia, dislipidemia, sobrepeso, obesidad y tabaco (fumado, masticado, vaporizado), junto con un estado proinflamatorio y procoagulante, son los principales factores de riesgo relacionados con la enfermedad cardiovascular aterosclerótica. Objetivo y métodos: Basándose en su experiencia en cardiología, prevención cardiovascular y enfermedades cardiometabólicas, un grupo de expertos de las Améri- cas se unió para desarrollar estas recomendaciones prácticas para la evaluación y tratamiento óptimos de los factores de riesgo cardiometabólicos residuales en América Latina, utilizando una metodología Delphi modificada con el objetivo de generar una guía integral de pautas para la reducción del riesgo cardiometabólico, mediante la medicina personalizada y la decisión centrada en el paciente teniendo en cuenta la relación costo-beneficio. El proceso fue bien definido para evitar conflictos de intereses que podrían sesgar la discusión y las recomendaciones. Resultados: La reducción del riesgo resid- ual debe considerar opciones terapéuticas adaptadas a las necesidades específicas del paciente, basadas en 5 objetivos de tratamiento: lipoproteínas ricas en triglicéridos inflamación, metabolismo de la glucosa, presión arterial alta y estado protrom- bótico. El Control integral de todos los factores de riesgo cardiometabólicos debe ser una prioridad para hacer frente a este importante problema de salud pública y prevenir las muertes prematuras. Las recomendaciones de este documento abordan el tratamiento basado en evidencia del riesgo cardiometabólico y están destinadas a la aplicación clínica en los países de América Latina.pdfengPermanyerAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Archivos de Cardiología de México(2021)Residual riskCardiovascular riskCardiometabolic risk factorsAtherosclerotic cardiovascular diseaseInflam- mationThrombosisRiesgo residualRiesgo cardiovascularRiesgo cardiometabólicoEnfermedad cardiovascular ateroscle- róticaInflamaciónTrombosisLatin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE)Consenso latinoamericano para el manejo del riesgo residual cardiometabólico. Consenso realizado por la Academia Latinoamericana de Lipidología y Riesgo Cardiometabólico (ALALIP), con el aval de la Sociedad Interamericana de Cardiología (SIAC), la Sociedad Interamericana de Aterosclerosis (IAS) y el Colegio Panamericano de Endotelio (PACE)info:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of di- sease study 2017. Lancet. 2018;392:1736-88.Januzzi JL Jr., Ahmad T, Binder LG, Hucker WJ, Kumbhani DJ, Maddox TM. et al. 2019 Methodology for creating expert consensus decision pathways: a report of the American college of cardiology. J Am Coll Cardiol. 2019;74:1138-50.Crawford M, Wright G. Delphi method. In: Wiley StatsRef: statistics Re- ference Online. United States: Wiley; 2016. p. 1-6.Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual risk reduction initiative (R3i). Residual ma- crovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.Averna M, Stroes E, Alterations Beyond LDL Expert Working Group. How to assess and manage cardiovascular risk associated with lipid altera- tions beyond LDL. Atheroscler Suppl. 2017;26:16-24.Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532-61.Ganda O, Bhatt D, Mason P, Miller M, Boden W. Unmet need for adjunc- tive dyslipidemia therapy in hypertriglyceridemia management. JACC. 2018;72:330-43.Ferrari R, Catapano AL. Residual cardiovascular risk. Eur Heart J Suppl. 2016;18:C2-12.Patel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018;137:2551-3.Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, The- roux P, et al, IMPROVE-IT Investigators. Ezetimibe added to statin the- rapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-97.Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, el al, FOURIER Steering Committee and Investigators. Evo- locumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22.Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097-107.Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al, CM REDUCE-IT Investigators. Cardiovascular risk reduction with icosa- pent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22.Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballan- tyne C, et al, CANTOS Trial Group. Antiinflammatory therapy with cana- kinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31.Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outco- mes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Eur Heart J. 2020;41:4092-9.Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497-505.Nidorf SM, Fiolet AT, Mosterd A, Eikelboom JW, Schut A, Opstal TS, et al, LoDoCo2 Trial Investigators. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838-47.Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890-900.Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in Type 2 diabetes: a me- ta-analysis. Medicine (Baltimore). 2019;98:e18245.Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8-16.Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual anti- platelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of cardiology/ American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2016;68:1116-39.Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al, PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800.Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestako- vska O, et al, COMPASS Investigators. Rivaroxaban with or without as- pirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319-30.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income coun- tries (PURE): a prospective cohort study. Lancet. 2020;395:795-808.Rana JS, Liu JY, Moffet HH, Boklage SH, Khan I, Karter AJ. Risk of in- cident atherosclerotic cardiovascular disease events by achieved athero- genic lipid levels among 62,428 statin-treated individuals with diabetes mellitus. Am J Cardiol. 2018;122:762-7.Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in pa- tients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3:823-8.Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular di- sease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society con- sensus panel. Eur Heart J. 2017;38:2459-72.Mundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VW, Iruela-Arispe ML, et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc Res. 2018;114:35-52.Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduc- tion among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289-97.Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic car- diovascular disease: new insights from epidemiology, genetics, and bio- logy. Circ Res. 2016;118:547-63.Masana L, Girona J, Ibarretxe D, Rodríguez-Calvo R, Rosales R, Vallvé JC, et al. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. J Clin Lipi- dol. 2018;12:292-9.e3.Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, EBBIN- GHAUS Investigators. Cognitive function in a randomized trial of evolo- cumab. N Engl J Med. 2017;377:633-43.Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al, FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhi- bitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962-71.Ditlev C, Johannesen L, Bødtker Mortensen M, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77:1439-50.Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY) II. Am Heart J. 2006;151:975.e1-9.Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Residual cardiovascu- lar risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study. Clinicoecon Outcomes Res. 2016;8:649-55.Johansen CT, Hegele RA. Using mendelian randomization to determine causative factors in cardiovascular disease. J Intern Med. 2013;273:44-7.Ponte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, Lopez-Jaramillo P, Wyss-Q FS, Pintó X, et al. Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment: expert’s position paper made by the Latin American academy for the study of lipids (ALALIP) endorsed by the inter-American society of cardiology (IASC), the South American society of cardiology (SSC), the Pan-American college of endothelium (PACE), and the international atherosclerosis society (IAS). Int J Cardiol. 2017;243:516-22.Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The ARBITER 6-HALTS trial (Arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL Treatment Stra- tegies in Atherosclerosis): final results and the impact of medication adhe- rence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721-6.AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chait- man BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr., Grimm RH Jr., Cutler JA, et al. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, et al. Fe- nofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowe- ring in diabetes (FIELD) study. Diabetes Care. 2009;32:493-8.ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-18.The ASCEND Study Collaborative Group. Effects of n-3 fatty acid supple- ments in diabetes mellitus. N Engl J Med 2018;379:1540-50.Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al, Omega-3 Treatment Trialists’ Collaboration. Associations of Ome- ga-3 fatty acid supplement use with cardiovascular disease risks: me- ta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3:225-34.Ponte-N C, Machado HL. Lipidología y prevención cardiovascular La era de las combinaciones llegaron para quedarse. JACC Spanish Ed 2020;1:120-3.Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and effica- cy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circu- lation. 2016;133:1073-80.Thanassoulis G, Sniderman AD, Pencina MJ. A long-term benefit approach vs standard risk-based approaches for statin eligibility in pri- mary prevention. JAMA Cardiol. 2018;3:1090-5.Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin out- come trials. Lancet. 2018;392:1311-20.Verbeek R, Hoogeveen RM, Langsted A, Stiekema LC, Verweij SL, Hovingh GK, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39:2589-96.Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9:25.Low Wang CC, Everett BM, Burman KD, Wilson PW. Cardiovascular safety trials for all new diabetes mellitus drugs? Circulation. 2019;139:1741-3.Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2017;24:44-51.Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovas- cular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-17.Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al, The EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373: 2117-28.Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al, CANVAS Program Collaborative Group. Canagliflozin and cardio- vascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377: 644-57.Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al, MS DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular out- comes in Type 2 diabetes. N Engl J Med. 2019;380:347-57.Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, et al. Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EM- PA-REG OUTCOME trials: a systematic review. Rev Cardiovasc Med. 2018;19:41-9.Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al, EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outco- mes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24.McMurray JJ, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Lang- kilde AM, et al, DAPA-HF Committees and Investigators. A trial to eva- luate the effect of the sodium-glucose co-transporter 2 inhibitor dapagli- flozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21: 665-75.Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al, DAPA-CKD Trial Committees and Investigators. Dapagli- flozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46.Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al, LEADER Steering Committee, LEADER Trial Investiga- tors. Liraglutide and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375:311-22.Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outco- mes in patients with Type 2 diabetes. N Engl J Med. 2016;375:1834-44.Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al, REWIND Investigators. Dulaglutide and cardiovascular outcomes in Type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121-30.Wyss F, Coca A, Lopez-Jaramillo P, Ponte-Negretti C. The Task Force for the Management of Arterial Hypertension of the Interamerican Socie- ty of Cardiology (IASC), Reviewers from the European Society of Hyper- tension (ESH), Latin-American Society of Hypertension (LASH), and the Spanish Society of Cardiology (SSC). Position statement of the Intera- merican society of cardiology (IASC) on the current guidelines for the prevention, diagnosis and treatment of arterial hypertension 2017-2020. Int J Cardiol Hypertens. 2020;6:100041.Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Za- harris E, CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752-76.Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, et al. Rationale and design for the vascular outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018;199:83-91.Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al, COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomi- sed, double-blind, placebo-controlled trial. Lancet. 2018;391:219-29.Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al, ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.Nocon M, Hiemann T, Müller-Riemenschneider F, Thalau F, Roll S, Wi- llich SN. Association of physical activity with all-cause and cardiovascu- lar mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2008;15:239-46.American Heart Association. Council on Lifestyle and Cardiometabolic Health. Available from: https://www.professional.heart.org/professional/ MembershipCouncils/ScientificCouncils/UCM_322856_Council-on-Lifes- tyle-and-Cardiometabolic-Health.jsp. [Last accessed on 2018 Sep 19Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coro- nary heart disease. Arch Intern Med. 2009;169:659-69.Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, et al. 2018 ACC expert consensus decision pathway on to- bacco cessation treatment: a report of the American college of cardiolo- gy task force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72:3332-65.Sosa-Liprandi Á, Sosa Liprandi MI, Alexánderson E, Avezum Á, Lanas F, López-Jaramillo JP, et al. Clinical impact of the polypill for cardiovascular prevention in Latin America: a consensus statement of the inter-American society of cardiology. Glob Heart. 2019;14:3-16.e1.ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf1666372https://bonga.unisimon.edu.co/bitstreams/5494ae4f-70a0-4966-a727-c70d23acd39b/downloadf5f0ec352ebd75d5f64ebfa2dfa2dd55MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/fa4e43eb-82a1-495c-8e0d-068291d46b3f/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/3a366dc6-e17b-422e-a679-b3937fab61cb/download733bec43a0bf5ade4d97db708e29b185MD53TEXTLatin American Concensus on management of residual cardiometabolic risk.pdf.txtLatin American Concensus on management of residual cardiometabolic risk.pdf.txtExtracted texttext/plain75994https://bonga.unisimon.edu.co/bitstreams/13492803-ccda-44d2-86b4-42af5252e7c0/download4e5ad6cbcf1a9173a96e931766174891MD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain77265https://bonga.unisimon.edu.co/bitstreams/3bf574ff-c691-4733-8497-9f7e4aac5071/download4ca57a5ab58253a140e7f00f4147b711MD56THUMBNAILLatin American Concensus on management of residual cardiometabolic risk.pdf.jpgLatin American Concensus on management of residual cardiometabolic risk.pdf.jpgGenerated Thumbnailimage/jpeg21431https://bonga.unisimon.edu.co/bitstreams/31d5e601-c3e2-4041-b2a2-bb7463e57463/download2c444f42af7e3ccbc203417cd8659f1cMD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg6394https://bonga.unisimon.edu.co/bitstreams/f6d2c737-6d0e-454f-a5ae-63f00e186319/downloadc12ef096a4a870f1ca8ed66c444dcbd0MD5720.500.12442/7944oai:bonga.unisimon.edu.co:20.500.12442/79442024-08-14 21:51:37.886http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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

Publicaciones similares